Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
International Journal of Medicinal Mushrooms
Facteur d'impact: 1.423 Facteur d'impact sur 5 ans: 1.525 SJR: 0.431 SNIP: 0.716 CiteScore™: 2.6

ISSN Imprimer: 1521-9437
ISSN En ligne: 1940-4344

Volume 22, 2020 Volume 21, 2019 Volume 20, 2018 Volume 19, 2017 Volume 18, 2016 Volume 17, 2015 Volume 16, 2014 Volume 15, 2013 Volume 14, 2012 Volume 13, 2011 Volume 12, 2010 Volume 11, 2009 Volume 10, 2008 Volume 9, 2007 Volume 8, 2006 Volume 7, 2005 Volume 6, 2004 Volume 5, 2003 Volume 4, 2002 Volume 3, 2001 Volume 2, 2000 Volume 1, 1999

International Journal of Medicinal Mushrooms

DOI: 10.1615/IntJMedMushr.v4.i3.30
8 pages

A Phase I/II Study of a Ganoderma lucidum (Curt.: Fr.) P. Karst. Extract (Ganopofy) in Patients with Advanced Cancer

Yihuai Gao
Institute of Food, Nutrition and Human Health, Massey University; Landcare Research, Private Bag 92170, Auckland, New Zealand
Shufeng Zhou
Division of Pharmacy, School of Life Sciences, Faculty of Science, Queensland University of Technology, Australia; Department of Pharmacy, Faculty of Science, National University of Singapore; University of South Florida FL 33612, USA
Guoliang Chen
Division of Traditional Chinese Medicine, New Zealand Institute of Natural Medicines, Auckland, New Zealand
Xihu Dai
Department of Internal Medicine, Fuzhou General Hospital of Nanjing Military Region of the Peoples' Liberation Army, Fuzhou, R.P. China
Jingxian Ye
Department of Integrated Medicine. Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, R.P. China


In vitro and animal studies have established that the polysaccharide fractions of Ganoderma lucidum have potential antitumor activity and inhibitory effect on tumor metastasis. Ganopoly (crude polysaccharide fractions extracted from G. lucidum by patented technique, kindly provided by Encore International Ltd., Auckland, NZ) has demonstrated immunomodulating and tumor inhibitory effects in in vitro and mouse models. A clinical trial was conducted to evaluate the efficacy and safety of Ganopoly in patients with advanced cancer. One hundred and forty-three patients with advanced, previously treated cancer were enrolled. Eligibility criteria included confirmation of diagnosis, objectively measurable disease, Eastern Cooperative Oncology Group performance status of 0 to 2, life expectancy of 12 weeks or greater, no recent or concomitant anticancer therapy, and informed consent. Patients underwent evaluation of the extent of disease, quality of life, hematologic, biochemical, and selected immune function studies at baseline and after 6 and 12 weeks of Ganopoly therapy. Standard criteria were used to evaluate adverse events and response. Ganopoly was given orally at 1800 mg three times daily. Twenty-seven patients were not assessable for response and toxicity because they were lost to follow-up or refused further therapy before 12 weeks of treatment. Of the 100 fully assessable patients, 46 patients (32.2%) had progressive disease (PD) before or at the 6-week evaluation point (range, 5 days—6 weeks). Sixteen patients (11.2%) developed PD between 6 and 12 weeks of therapy. No objective (partial or complete) responses were observed, but 38 of 143 patients (26.6%) had stable disease (SD) for 12 weeks or more (range, 12-50 weeks). There was no significant change in the FACT-G scores in 85 assessable patients. However, palliative effects on cancer-related symptoms, such as sweating and insomnia, have been observed in many patients. In the group of patients with SD, FACT-G scores improved in 23 patients, were unchanged in 5 patients, and declined in 1 patient. Within this group, the median change from the baseline score to the 6- and 12-week score was +7.6 and +10.3 score, both statistically significant (P < 0.05). No significant changes of the selected immune function parameters were observed in 75 assessable patients. However, in the group of 32 patients with SD for 12 weeks or more, Ganopoly significantly increased lymphocyte mitogenic reactivity to concanavalin A and phytohemagglutinin by 28 ± 7.3% (P < 0.05) and significantly enhanced natural killer cell activity by 25 ± 5.9% (P < 0.05). Five adverse events (grade 1) were recorded, 3 of which were gastrointestinal (nausea, 2; diarrhea, 1). The results indicate that Ganopoly may have an adjunct role in the treatment of patients with advanced cancer, although objective responses were not observed in this study.

Articles with similar content:

A Randomized, Placebo-Controlled, Multicenter Study of Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) Polysaccharides (Ganopoly®) in Patients with Advanced Lung Cancer
International Journal of Medicinal Mushrooms, Vol.5, 2003, issue 4
Guoliang Chen, Jingxian Ye, Yihuai Gao, Shufeng Zhou, Xihu Dai
Chemopreventive and Tumoricidal Properties of Ling Zhi Mushroom Ganoderma lucidum (W. Curt.:Fr.) Lloyd (Aphyllophoromycetideae). Part I. Preclinical and Clinical Studies (Review)
International Journal of Medicinal Mushrooms, Vol.6, 2004, issue 2
He Gao, Jin Lan, Yihuai Gao, Wenbo Tank, Shufeng Zhou
Immune Responses to Water-Soluble Ling Zhi Mushroom Ganoderma lucidum (W.Curt.:Fr.) P. Karst. Polysaccharides in Patients with Advanced Colorectal Cancer
International Journal of Medicinal Mushrooms, Vol.7, 2005, issue 4
Guoliang Chen, He Gao, Jingxian Ye, Yihuai Gao, Min Huang, Eli Chan, Wenbo Tang, Shufeng Zhou, Xihu Dai
Clinical Trials for Medicinal Mushrooms: Experience with Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Lingzhi Mushroom)
International Journal of Medicinal Mushrooms, Vol.7, 2005, issue 1&2
Yihuai Gao, Eli Chan, Shufeng Zhou
A Phase I/II Study of Ling Zhi Mushroom Ganoderma lucidum (W.Curt.:Fr.)Lloyd (Aphyllophoromycetideae) Extract in Patients with Type II Diabetes Mellitus
International Journal of Medicinal Mushrooms, Vol.6, 2004, issue 1
Jin Lan, Jingxian Ye, Yihuai Gao, Shufeng Zhou, Xihu Dai